Skip to main content


Figure 2 | Arthritis Research & Therapy

Figure 2

From: Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study

Figure 2

Percentage of patients experiencing no or mild pain following administration of study medication. Pain assessments made using a 5-point Likert scale. *P < 0.05 for canakinumab 150 mg vs triamcinolone acetonide 40 mg. CI, confidence interval; LS, least-squares.

Back to article page